NGL Fine Chem Ltd Q3 FY26 – ₹127 Cr Revenue, 1,100% PAT Explosion & Yet ROE Stuck at 6.6%… What’s Cooking Here?
1. At a Glance – The Curious Case of “Booming Profits, Lazy Returns”
If you walked into NGL Fine Chem’s Q3 FY26 results like a Bollywood interval scene, you’d think the hero just discovered hidden treasure. Revenue up 43% YoY, PAT up a ridiculous 1,129% YoY, margins suddenly behaving like a disciplined IIT student… and yet… the ROE is still chilling at 6.68% like it’s on Goa vacation.
This is one of those companies where numbers scream “turnaround!” but ratios whisper “relax, don’t get too excited.”
It’s like your friend who suddenly starts going to the gym, posts transformation pics, but still eats biryani at 2 AM.
So what exactly is happening here?
Is this a genuine margin recovery story? Is capex finally kicking in? Or is this just a temporary spike before reality returns like Monday morning?
Let’s investigate like a suspicious auditor who trusts nobody—not even Excel.
2. Introduction – Pharma Niche Player or Silent Compounder?
NGL Fine Chem is not your typical “big pharma” story. No blockbuster drugs, no USFDA drama, no celebrity CEO interviews.
Instead, it quietly operates in the animal healthcare API space—basically making drugs for animals. Yes, cows, goats, poultry… the real Indian GDP contributors.
And guess what?
92% revenue comes from Animal APIs
Human APIs are just a side hustle
Formulations and intermediates? Even smaller
So this is a highly focused niche business.
Now here’s the interesting part:
They supply to 5 of the top 10 global animal healthcare companies (basically B2B muscle). They have 15% to 50%+ market share in key APIs. Exports contribute 70–75% of revenue.
Sounds impressive, right?
But then you look at profitability history:
PAT growth (3 years): -30%
ROE (last year): ~7%
EBITDA margin: collapsed from ~16% to ~7% recently
So clearly, this company has been through some “identity crisis phase.”
Now Q3 suddenly shows margin recovery.
So the big question: 👉 Is this a comeback… or just a good quarter?
3. Business Model – WTF Do They Even Do?
Let’s simplify this like explaining to your cousin who thinks pharma means Crocin.
NGL makes:
Veterinary APIs (bulk drugs for animals)
Intermediates (raw materials for APIs)
Some formulations
Basically, they are the backend factory of the animal pharma world.
They don’t sell branded medicines. They sell ingredients to big pharma companies.
Think of them as:
👉 The flour supplier in a pizza business 👉 Not Domino’s… but the guy supplying wheat
Now here’s what makes it interesting:
95% in-house manufacturing
Strong backward integration via subsidiary Macrotech
Focus on cost efficiency and volume
But here’s the catch:
Top 3 products = ~28% revenue
Top 10 products = ~65% revenue
That’s concentration risk screaming softly in the background.
Let me ask you:
👉 If 3 products drive your revenue, are you diversified or just pretending?
4. Financials Overview – The “Wait… What Just Happened?” Quarter
